ExploreWatchlistsPricing
  1. JP-listed companies
  2. SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
  3. Financials
  4. Cash from investing

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395)

Market cap
¥58.9B
P/E ratio
16.5x
Provides drug development testing services to pharmaceutical companies and operates innovative intranasal drug delivery technology through spinout companies.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash from investing (Million JPY)YoY (%)
Mar 31, 2025-11,691+69.25%
Mar 31, 2024-6,908+16.48%
Mar 31, 2023-5,931+38.94%
Mar 31, 2022-4,269+1488.85%
Mar 31, 2021-269-81.54%
Mar 31, 2020-1,455-434.70%
Mar 31, 2019435-48.11%
Mar 31, 2018838-366.65%
Mar 31, 2017-314-124.43%
Mar 31, 20161,286-217.68%
Mar 31, 2015-1,093

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat